eligibility_summary
Adults (≥18) with relapsed/refractory mantle cell lymphoma with t(11,14)/cyclin D1+, needing treatment, evaluable disease, ECOG 0–2, and adequate blood counts/coagulation/liver/renal function. Negative pregnancy test, strict contraception, REMS, aspirin-tolerant, consent, follow-up, blood samples. Exclude: pregnancy, recent auto SCT/CAR-T (≤90 d), prior allo SCT, CNS MCL, other MCL therapy, interacting drugs/foods, HIV, active HBV/HCV, serious comorbidity, recent MI/stroke/surgery/live vax, bleeding risk, other active cancers, inability to swallow.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase II single-arm trial in relapsed/refractory mantle cell lymphoma testing: 1) Tafasitamab (tafasitamab-cxix, IV humanized anti-CD19 monoclonal antibody). Mechanism: binds CD19 on malignant B cells, inducing antibody-dependent cellular cytotoxicity/phagocytosis and direct cytotoxic signaling. 2) Lenalidomide (oral small-molecule immunomodulatory drug, IMiD). Mechanism: binds cereblon E3 ligase, degrades IKZF1/3, enhances T- and NK-cell activation and ADCC. 3) Venetoclax (oral small-molecule BCL-2 inhibitor, BH3 mimetic). Mechanism: blocks BCL-2 to trigger mitochondrial apoptosis. Targets/pathways: CD19+ B cells, BCL-2 anti-apoptotic pathway, cereblon–IKZF axis and immune effector (NK/T) activation.